Characterization of a single-cycle rabies virus-based vaccine vector

scientific article

Characterization of a single-cycle rabies virus-based vaccine vector is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.01870-09
P932PMC publication ID2826042
P698PubMed publication ID20053743

P50authorMatthias J. SchnellQ61864440
James P McGettiganQ91280200
P2093author name stringElizabeth J Faul
Phyllis Flomenberg
Emily A Gomme
P2860cites workConcepts in the pathogenesis of rabiesQ39965361
Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.Q40361792
The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protectionQ40390611
The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitopeQ40716670
Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo studyQ40860222
Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system.Q41689082
Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.Q42036085
Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicityQ43178486
SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vectorQ45395971
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like diseaseQ45406650
Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responsesQ45413779
Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcriptionQ45802541
Measurement of polyclonal and antigen-specific cytotoxic T cell functionQ46630058
A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing CellsQ57077896
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime–boost approachQ57165945
Global epidemiology of HIVQ57871015
Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C VirusQ27469800
Interleukin-10 determines viral clearance or persistence in vivoQ27486832
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cellsQ29616205
HIV-prevention science at a crossroads: advances in reducing sexual risk.Q30378142
Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolatesQ33839981
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vectorQ33854615
Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodiesQ33911986
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vectorQ34092753
Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.Q34334320
Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenicQ34461764
Replication-defective viruses as vaccines and vaccine vectorsQ34477918
Budding of rabies virus particles in the absence of the spike glycoproteinQ34662773
HIV-1 vaccines: the search continuesQ34876150
A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infectionQ35853085
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challengeQ36129034
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceQ36423935
Genetic recombination during coinfection of two mutants of human respiratory syncytial virusQ36474033
The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spreadQ36483804
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialQ36618096
Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein geneQ37068893
Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.Q37174356
Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particlesQ37249987
Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike proteinQ37250302
Retrograde neuronal tracing with a deletion-mutant rabies virusQ37370635
Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virusQ37600266
Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaqueQ37683291
Differential transcription attenuation of rabies virus genes by intergenic regions: generation of recombinant viruses overexpressing the polymerase geneQ39592571
P433issue6
P921main subjectvector-borne diseaseQ2083837
rabiesQ39222
rabies virusQ698976
P304page(s)2820-2831
P577publication date2010-01-06
P1433published inJournal of VirologyQ1251128
P1476titleCharacterization of a single-cycle rabies virus-based vaccine vector
P478volume84

Reverse relations

cites work (P2860)
Q38960717A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region
Q36356863A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence
Q35803316A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus
Q34414740An anterograde rabies virus vector for high-resolution large-scale reconstruction of 3D neuron morphology
Q27334697Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine
Q42276697Axonal and subcellular labelling using modified rabies viral vectors
Q41923775Combining confocal and atomic force microscopy to quantify single-virus binding to mammalian cell surfaces.
Q34806497Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses
Q35184639Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine
Q41217724Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity
Q39529861Development of recombinant rabies viruses vectors with Gaussia luciferase reporter based on Chinese vaccine strain CTN181.
Q37798009Experimental rabies vaccines for humans
Q37951526From brain passage to cell adaptation: the road of human rabies vaccine development
Q36210186Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein
Q36312553Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression
Q35275167Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
Q34261441Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus
Q28397551Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways
Q38266413RNA-based viral vectors
Q39633419Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV.
Q37877958Rabies virus as a research tool and viral vaccine vector
Q42051356Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice.
Q37543755Reverse Genetics Approaches to Control Arenavirus.
Q38363535Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics
Q34992537Rhabdovirus-based vaccine platforms against henipaviruses
Q35150964Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses
Q90024491Vaccination with a Single-Cycle Respiratory Syncytial Virus Is Immunogenic and Protective in Mice
Q38885624Viral and Synthetic RNA Vector Technologies and Applications
Q47239972Virus stamping for targeted single-cell infection in vitro and in vivo

Search more.